SARS-CoV-2 is the agent responsible for COVID-19. The infection can be dived into three phases: mild infection, the pulmonary phase and the inflammatory phase. Treatment options for the pulmonary phase include: Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir. The inflammatory phase includes therapeutic options like Tocilizumab, Anakinra, Baricitinib, Eculizumab, Emapalumab and Heparin. Human clinical trials are starting to show some results, in some cases like that of Remdesivir these are controversial. Coagulopathy is a common complication in severe cases, inflammation and coagulation are intertwined and cross-talking between these two responses is known to happen. A possible amplification of this cross-talking is suggested to be implicated in the severe cases that show both a cytokine storm and coagulopathy.

SARS-CoV-2是负责COVID-19的代理。感染可分为三个阶段：轻度感染，肺部阶段和炎性阶段。肺部疾病的治疗选择包括：羟氯喹，雷姆昔韦，洛匹那韦/利托那韦。炎症期包括治疗选择，例如Tocilizumab，Anakinra，Baricitinib，Eculizumab，Emapalumab和肝素。人体临床试验开始显示出一些结果，在某些情况下，如瑞姆昔韦，则存在争议。凝血障碍是严重病例中的常见并发症，炎症和凝血相互交织，并且已知这两种反应之间会发生串扰。建议在显示细胞因子风暴和凝血病的严重病例中牵涉这种串扰。